Spyre Therapeutics, Inc. 8-K

What Happened

• Spyre Therapeutics (SYRE) announced it entered into an underwriting agreement and completed a public offering of common stock, selling 6,500,000 shares at $62.00 per share. The underwriters exercised their 30-day option in full to purchase an additional 975,000 shares, and the offering closed on April 16, 2026. Gross proceeds to the company were approximately $463.5 million before underwriting discounts, commissions and offering expenses. Lead underwriters included Jefferies, Goldman Sachs, Evercore and Guggenheim.

Key Details

• Shares sold: 6,500,000 primary shares; option exercised for 975,000 additional shares (total 7,475,000 shares).
• Price: $62.00 per share.
• Gross proceeds: ~ $463.5 million (before fees and expenses).
• Filing basis: Offering made under the company’s Form S-3 shelf registration (File No. 333-293600); final prospectus supplement dated April 14, 2026.

Why It Matters

• The offering materially increases Spyre’s cash runway, allowing the company to fund preclinical and clinical work, manufacturing, and Phase 3 readiness for its antibody programs in inflammatory bowel disease and rheumatic diseases, as well as general corporate purposes.
• For investors, the raise reduces near-term financing risk but dilutes existing shareholders because new shares were issued. The transaction also reflects underwriter support (option fully exercised), and the company agreed to customary indemnities to the underwriters.